Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class
Globe Newswire17-02-2023, 23:58
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26